However, the expanded spectrum of phenotype accompanying germline alterations in CDKN2A suggests that it may be relevant to consider CDKN2A as a candidate for tumor predisposition beyond melanoma and pancreatic cancer in clinical practice. Here, CDKN2A is linked to familial pancreatic carcinoma.